Francis A. Farraye, MD, MSc

Professor of Medicine

Director, Inflammatory Bowel Disease Center

Division of Gastroenterology and Hepatology

Mayo Clinic, Florida

Francis A. Farraye, MD, MSc is Director of the Inflammatory Bowel Disease Center in the Division of Gastroenterology and Hepatology and Professor of Medicine at the Mayo Clinic in Jacksonville, FL.  Dr. Farraye has authored or co-authored over 600 original scientific manuscripts, chapters, reviews, and abstracts. He co-wrote the text, Curbside Consultation in Inflammatory Bowel Disease and Gastrointestinal Emergencies. His newest book for patients is Mayo Clinic on Crohn's Disease and Ulcerative Colitis. He is the Editor in Chief for IBD Journal Scan published weekly by the ASGE. Dr. Farraye is a Fellow in the ASGE, AGA, Crohn’s and Colitis Foundation and a Master of the ACG. He has served on numerous national and international committees and is presently Vice Chair of the IBD committee for the WGO. The New England Crohn's and Colitis Foundation named Dr. Farraye Humanitarian of the Year in 2003 and in  2020 was a recipient of the Lifetime Achievement Award from the New England Crohn's and Colitis Foundation. He is the 2026 Florida Crohn’s and Colitis Foundation Health Care Professional Honoree. 

Dr. Farraye is a consultant for Astellas, Avalo Therapeutics, Bausch, Biocon, Braintree Labs, Celltrion, Cristcot,  GI Reviewers, IBD Educational Group, Iterative Health, Janssen, Moderna, Merck, Metaphore Biotechnologies and  Pfizer. He is a member of a DSMB for Eli Lilly Pharmaceuticals and MoonLake Immunotherapeutics.

Off-Label Discussion: The speaker does not plan on discussing unlabeled/investigational uses of a commercial product.

Planning Committee

The following planning committee members have no relevant financial relationships to disclose.

• Linda Baer, MSPH, CHCP; BU CCE Associate Director
• Juanita Belton, PA; Physician Associate Accreditation Reviewer
• Michael Burk, BS; BU CCE Senior Operations Manager
• Amy Donegan , APRN, CPNP-PC; Member of the BU Hub Team and Nursing Accreditation Advisor
• Sharmeel Wasan, MD; Program Course Director

Dr. Spiewak, PharmD, MCSR-RPh, MSCS; ACPE Accreditation Advisor, discloses that he is a speaker, consultant, and on the advisory panels for Abbvie, Celltrion, and Johnson & Johnson.

Disclosure Policy

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 
 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
 

Disclaimer Policy

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS.  ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE.  TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS.  IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS.  IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.